NCT00699920已完成4 期
A Randomised Study to Compare a Fixed Dose Combination of Artesunate Plus Amiodaquine (Coarsucam) Versus a Fixed Dose Combination of Artemether Plus Lumefantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During the 2 Years of Follow-up, in Children in Uganda.
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 413
- 试验地点
- 1
- 主要终点
- PCR corrected and uncorrected clinical and parasitological cure rate
研究概览
简要总结
Primary objective is to demonstrate the non-inferiority of PCR (Polymerase Chain Reaction) adjusted adequate clinical and parasitological response at Day 28 of Coarsucam versus Coartem, based on the first malaria attack of each patient.
Secondary objectives:
For the first attack:
To compare the 2 groups of treatment in terms of:
- Day 42 efficacy
- Parasitological and fever clearance
- Clinical and Biological tolerability
- Evolution of gametocyte carriage
For attack 2nd and following:
To compare the 2 groups of treatment in terms of:
- Day 28 and Day 42 clinical and parasitological effectiveness
- Clinical and Biological tolerability
- Proportion of patients without fever at Day 3
- Proportion of patients without parasites at Day 3
- Evolution of gametocyte carriage
- Compliance
During the total follow up of the cohort:
To compare the 2 groups of treatment in terms of:
- Treatment incidence density
- Impact of repeated treatment on clinical and biological tolerability
- Impact on anaemia
- Impact on Hackett score.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Months 至 59 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Specific inclusion criteria for initial enrollment:
- •Confirmed mono infection with Plasmodium falciparum, with parasite density ≥2000 asexual forms per µl of blood,
- •Inclusion criteria for each attacks:
- •Body weight ≥5 kg
- •Able to be treated by oral route
- •Fever (axillary temperatur ≥37.5 degrees Celsius) at D0 or history of fever within the previous 24 hours
- •Confirmed Plasmodium falciparum infection with positive paratesimia
- •Haemoglobin value ≥5.0 g/dl
排除标准
- •Specific exclusion criteria for initial enrollment:
- •Patient participating in another ongoing clinical trial
- •Allergy to one of the investigational medicinal products
- •History of hepatic and (or) haematological impairment during treatment with amodiaquine
- •History of cardiac disease
- •Concomitant febrile illness
- •Exclusion criteria for each attacks:
- •Presence of at least one danger sign of malaria: recent history of convulsions (1-2 within 24h), unconsciousness state, lethargy, unable to drink or breast feed, vomiting everything, unable to stand/sit due to weakness
- •Severe concomitant disease or known disturbances of electrolyte balance such as hypokalaemia or hypomagnesaemia
- •Intake of medication metabolized by cytochrome CYP 2D6 (e.g. metoprolol, flecainide, imipramine, amitriptyline, clomipramine) at the time of inclusion
- •Intake of drugs known to inhibit CYP 2A6 (e.g. methoxsalem, pilocarpine, tranylcypromine) and/or 2C8 cytochromes (e.g. trimethoprim, ritonavir, ketoconazole, montelukast, gemfibrozil) at the time of inclusion
- •Intake of medication known to prolong the QTc interval, such as class IA and III antiarrythmics, neuroleptics, antidepressant agents, certain antibiotics including drugs in the macrolide class, fluoroquinolones, imidazole and triazole, antifungal agents, certain non-sedative anthistamines (terfenadine, astemizole) and cisapride at the time of inclusion
- •Patient having received artesunate + amiodaquine or artemether + lumefantrine at suitable dosage within the previous 2 weeks.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究组 & 干预措施
1
Experimental
Coarsucam double-layer artesunate/amiodaquine tablets
干预措施: Coarsucam (Drug)
2
Active Comparator
Coartem (artemether/lumefantrine) fixed-dose combination tablets
干预措施: Coartem (Drug)
结局指标
主要结局
PCR corrected and uncorrected clinical and parasitological cure rate
时间窗: At Day 28
次要结局
- PCR corrected and uncorrected clinical and parasitological cure rate(At Day 42)
- Fever and parasitological clearance evaluation by measuring the axillary temperature and monitoring paratesimia(At the first attack)
- Proportion of afebrile patients and proportion of patients without parasites(At Day 3 (following attacks))
- Evolution of baseline symptoms (Clinical efficacy measure)(During the study conduct)
- Number of residual tablets in blisters (compliance)(At the end of the study treatment)
- Treatment incidence density: comparison of the number of malaria attacks between the 2 arms(During the 2 years of follow-up)
- Mean delay between 2 attacks(during the 2 years of follow-up)
- Incidence and intensity of recorded AE(from the informed consent signed up to the end of the study)
- Biological tolerability (Hb, Bilirubin, ALAT, Creatinine, Leucocytes, Neutrophils and Platelets count)(During the study conduct)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets at Steady StateHealthy SubjectsBioavailabilityPharmacokineticsNCT01121926Labopharm Inc.30
已完成
1 期
A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily)HealthyNCT01121900Labopharm Inc.26
尚未招募
1 期
Bioequivalence Study of Sulfadoxine/Pyrimethamine 500/25 mg Dispersible TabletFastingNCT06522763Swiss Pharma Nigeria Limited46
已完成
不适用
RCT Comparing Ion Levels and Clinical Outcomes of A-Class BFH to Metal on Polyethylene Total Hip ReplacementHip JointArthroplastyOsteoarthritisNCT00911599Ottawa Hospital Research Institute60
已完成
1 期
Bioequivalence Study for Acarbose/Metformin FDCDiabetes Mellitus, Type 2NCT04065581Bayer24